PEGS Europe 2021: ProBioGen's Presentation shows how the DirectedLuck™ Transposase System streamlines Cell Line Development
Barcelona, Spain, November 3, 2021: ProBioGen is delighted to announce that today, its Chief Scientific Officer Dr. Volker Sandig has presented at 13th annual PEGS Europe Protein..
ProBioGen’s DirectedLuck™ Transposase Licensed by TOP15 Global BioPharma Company
Berlin, Germany, September 28, 2021: ProBioGen today announced the closing of a DirectedLuck Transposase Technology research license agreement with another global biopharma..
Nobelpharma signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX®
Berlin, Germany, August 12, 2021: ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIX vaccine production platform to..
ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®
Berlin, Germany and Bethesda, MD, USA, July 27, 2021: ProBioGen and ValenzaBio today jointly announced the initiation of a cell line development project involving the application..
Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line
Berlin, Germany, July 13, 2021: ProBioGen announced today that they have entered into a research license agreement with Heat Biologics for both ProBioGen's Transposase System..
ProBioGen and LAVA Therapeutics N.V. sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific
Berlin, Germany and Utrecht, Netherlands, June 22, 2021: ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a..
City of Hope takes a Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform
Berlin, Germany and Duarte, USA, June 9, 2021: ProBioGen AG has announced a commercial product license agreement with City of Hope, a world-renowned independent research and..
ProBioGen and Zag Bio™ Forge Strategic CMC Partnership to Advance Fc-Fusion Autoimmune Therapy
Jan 6, 2026
ProBioGen and Spica Therapeutics Announce Collaboration on GlymaxX-Enhanced CLD for Spica’s Clinical Development Candidate ST101
Dec 9, 2025
IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa
Oct 10, 2025
%20kooperieren%20im%20Berlin%20Center%20for%20Gene%20und%20Cell%20Therapies%20(BC%20GCT)-2.webp)
ProBioGen to Lead GMP Manufacturing Operations at Berlin Center for Gene and Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen und das Berlin Institute of Health in der Charité (BIH) kooperieren im Berlin Center for Gene und Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen Enters Agreement with Polpharma Biologics to Provide High-Performance Cell Line Development Services
May 7, 2025
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
